In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Start-Up Previews (4/00)

Executive Summary

A preview of the emerging health care companies profiled in the current issue of Start-Up. This month's profile group, Imaging and the Web features profiles of InPhact Inc., InSite One Inc., PhorMax Corp. and Stentor Inc. Plus these selected Start-Ups across Health Care: A-Med Systems Inc., Genitope Corp., Genmab AS and WebEBM Inc.

You may also be interested in...



Deal Watch: Merck's Busy Stretch Includes Collaborations With Dewpoint, Zymeworks

Bristol makes its own deal with Celgene ally Dragonfly, while Gilead ends virology partnerships with Durect and Precision BioSciences.

Ovid De-Risks Its Phase III Angelman Program With EU Angelini Partnership

FDA Proposes Updates To Peripheral Vascular Atherectomy Devices Guidance

US regulators are proposing updates to a guidance document they finalized in February for devices used to clear arteries of plaque. The updated language specifically addresses software interoperability, pyrogenicity and certain performance-testing requirements.

Related Companies

UsernamePublicRestriction

Register

LL1132247

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel